- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology | Clinical
Hillmen Analyzes Current and Upcoming Trials of BTK Inhibitors
February 24, 2021
During a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.
FDA Grants Priority Review to Ruxolitinib in Steroid-Refractory cGVHD
February 23, 2021
The FDA has accepted a supplemental New Drug Application for ruxolitinib and granted it Priority Review as a potential treatment option for adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease.
Omidubicel May Replace Current Standard in UCB Transplant Eligible Hematologic Malignancies
February 22, 2021
Omidubicel was faster than standard myeloablative umbilical cord blood transplantation and correlated with promising clinical benefit, according to phase 3 data.
Addition of Daratumumab to Rd/Vd Heightens MRD Negativity Rates in R/R Myeloma
February 18, 2021
High rates of sustained MRD negativity were achieved with daratumumab-containing combinations compared with the standard-of-care combinations, according to an exploratory analysis of 2 ongoing clinical trials.
Peri-Transplant Administration of Ruxolitinib Safe and Feasible in Myelofibrosis
February 17, 2021
Ruxolitinib is one of only 2 treatments for MF that significantly improved the survival of patients. Still oncologists see opportunity to prolong survival in these patients even more.
FDA Accepts sNDA for Zanubrutinib in Adult Waldenström’s Macroglobulinemia
February 17, 2021
The FDA has accepted a supplemental New Drug Application for zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.
Off-the-Shelf NK Immunotherapy Is Safe and Promising in B-Cell NHL With Chemotherapy and Transplant
February 16, 2021
Early antitumor activity was seen with cord blood–derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma, according to early results from a phase 2 trial.
Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?
February 15, 2021
In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.
Itolizumab Induces Durable Clinical Responses in Newly Diagnosed aGVHD
February 15, 2021
For the treatment of patients with newly diagnosed acute graft-versus-host disease, itolizumab has demonstrated promise in part A of the multicenter dose-ascending phase 1b/2 EQUATE study.
Ruxolitinib Exceeds Response, Survival, and Symptom Burden End Points in Chronic GVHD
February 12, 2021
Results from the phase 3, randomized REACH3 trial further demonstrated the benefit of ruxolitinib over BAT in rates for failure-free survival, symptom improvement, and duration of response.